Takeda: Angioedemas, Hereditary trials

The registry lists 60 Angioedemas, Hereditary studies with Takeda as lead sponsor. 4 are open to participants now and 35 have results posted.

Phase 1 5Phase 2 6Phase 3 26Phase 4 1No phase 23(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South KoreaRecruitingNCT07445087
• A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary AngioedemaRecruitingNCT07293364Not applicable
• A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in the Kingdom of Saudi ArabiaRecruitingNCT07263685
• A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in EgyptNot yet recruitingNCT07218393
• A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)CompletedNCT05460325Phase 3Results posted
• Expanded Access Program With Lanadelumab for Japanese People With Hereditary AngioedemaCompletedNCT04687137Phase 3Results posted
• A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary AngioedemaCompletedNCT04654351Phase 3Results posted
• A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-InhibitorCompletedNCT04444895Phase 3Results posted
• A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)CompletedNCT04206605Phase 3Results posted
• Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)CompletedNCT04180163Phase 3Results posted
• A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in ChildrenCompletedNCT04070326Phase 3Results posted
• FIRAZYR General Drug Use-Results Survey (Japan)CompletedNCT04057131Results posted
• A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese ParticipantsCompletedNCT03888755Phase 3Results posted
• Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)CompletedNCT02865720Phase 3Results posted
• Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAECompletedNCT02741596Phase 3Results posted
• Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult SubjectsCompletedNCT02663687Phase 1Results posted
• Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAECompletedNCT02586805Phase 3Results posted
• Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary AngioedemaCompletedNCT02584959Phase 3Results posted
• A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema ParticipantsCompletedNCT02093923Phase 1Results posted
• Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary AngioedemaCompletedNCT02052141Phase 3Results posted
• Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese VolunteersCompletedNCT02045264Phase 1Results posted
• Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema AttacksCompletedNCT01756157Phase 2Results posted
• A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human HyaluronidaseCompletedNCT01426763Phase 2Results posted
• A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary AngioedemaCompletedNCT01386658Phase 3Results posted
• CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12CompletedNCT01095510Phase 2Results posted
• A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE AdministrationCompletedNCT01095497Phase 2Results posted
• Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary AngioedemaCompletedNCT01059526Results posted
• C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) AttacksCompletedNCT01005888Phase 3Results posted
• EASSI - Evaluation of the Safety of Self-Administration With IcatibantCompletedNCT00997204Phase 3Results posted
• A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZECompletedNCT00914966Phase 4Results posted
• A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)CompletedNCT00912093Phase 3Results posted
• Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)CompletedNCT00500656Phase 3Results posted
• Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) AttacksCompletedNCT00462709Phase 3Results posted
• Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)CompletedNCT00457015Phase 3Results posted
• Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)CompletedNCT00456508Phase 3Results posted
• Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) AttacksCompletedNCT00438815Phase 3Results posted
• C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) AttacksCompletedNCT00289211Phase 3Results posted
• Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)CompletedNCT00262080Phase 3Results posted
• Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary AngioedemaCompletedNCT00097695Phase 3Results posted
• A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple CountriesCompletedNCT07251933
• A Study to Explore Hereditary Angioedema (HAE) Symptoms and Treatment Patterns in Korean PeopleCompletedNCT06587464
• A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in ChinaCompletedNCT06346899
• A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in CanadaCompletedNCT05578417
• A Survey of Icatibant in Pediatric Participants With Hereditary AngioedemaCompletedNCT05509569
• A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at HomeCompletedNCT05489640
• A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)Active, not recruitingNCT05469789
• A Survey of Lanadelumab in Participants With Hereditary AngioedemaActive, not recruitingNCT05397431
• A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in PolandCompletedNCT05147181
• A Study of the Burden of Illness and Treatment Patterns in Teenagers and Adults With Hereditary AngioedemaCompletedNCT04957641
• A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in ArgentinaCompletedNCT04955964
• A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term ProphylaxisCompletedNCT04861090
• Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and AdultsNo longer availableNCT04583007
• A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or IICompletedNCT04130191
• A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North AmericaCompletedNCT03845400
• A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy SubjectsCompletedNCT01923207Phase 1
• EDEMA2: Evaluation of DX-88's Effect in Mitigating AngioedemaCompletedNCT01826916Phase 2
• A European Post-Authorisation Observational Study Of Patients With Hereditary AngioedemaCompletedNCT01541423
• Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary AngioedemaWithdrawnNCT01253382Phase 2/3
• Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)CompletedNCT01034969
• Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema SubjectsCompletedNCT00432510Phase 1